Kenvue FY26 Q2 diluted EPS rises 9% to $0.24; net sales increase 3% vs year earlier to $3.96 billion - KVUE News | RalliesKenvue FY26 Q2 diluted EPS rises 9% to $0.24; net sales increase 3% vs year earlier to $3.96 billion
K
KVUE• Q2 results show higher EPS and sales
- Kenvue posted fiscal Q2 net income of $456 million, lifting diluted EPS 9% to $0.24 versus the prior-year quarter.
- Net sales rose 3% to $3.96 billion; organic sales increased 1.6%, including 0.9% value realization and 0.7% volume growth.
- Gross profit margin narrowed 0.7 percentage points to 58.2%, pressured by inflation and tariffs despite productivity gains.
CEO says transformation remains on track; Tylenol with Naproxen cleared
- CEO Kirk Perry said the transformation is on track as Kenvue works toward closing its Kimberly-Clark deal in Q4 2026.
- FDA cleared Tylenol with Naproxen, an OTC acetaminophen-naproxen combination with three-year exclusivity, expected to reach major U.S. retailers soon.
•
